New combo aims to halt sarcoma growth
NCT ID NCT05941325
First seen May 21, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This study tests a combination of fruquintinib (a drug that blocks blood vessel growth) and an immunotherapy for people with advanced bone and soft tissue sarcoma that cannot be removed by surgery. The goal is to see if the combo can slow or stop the cancer from growing. The trial planned to enroll 20 participants aged 12-70, but it is currently suspended.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR UNRESECTABLE LOCALLY ADVANCED BONE AND SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Shanghai No.6 People Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.